|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Therapy Trails-Other |
The Brain Tumor Center at Duke (C.D.T, S.G., K.B., M.W., S.T.-U., H.S.F.) and the Divisions of Neuro-Radiology (J.E.), Pathology (R.E.M.), and Neurosurgery (A.H.F.), Duke University Medical Center, Durham, NC 27710; and Pharmacia and Upjohn (R.B., L.L.M.), Kalamazoo, MI 49001
2 Address correspondence and reprint requests to Sridharan Gururangan, The Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710.
Abstract
A phase II study of irinotecan (CPT-11) was conducted at Duke University Medical Center, Durham, NC, to evaluate the activity of this agent in children with high-risk malignant brain tumors. A total of 22 children were enrolled in this study, including 13 with histologically verified recurrent malignant brain tumors (glioblastoma multiforme [GBM] 4, anaplastic astrocytoma 1, ependymoma 5, and medulloblastoma/primitive neuroectodermal tumor 3), 5 with recurrent diffuse pontine glioma, and 4 with newly diagnosed GBM. All patients with recurrent tumor had prior chemotherapy and/or irradiation. Each course of CPT-11 consisted of 125 mg/m2 per week given i.v. for 4 weeks followed by a 2-week rest period. Patients with recurrent tumors received therapy until disease progression or unacceptable toxicity. Patients with newly diagnosed tumors initially received 3 cycles of treatment to assess tumor response and then were allowed radiotherapy at physician's choice; patients who demonstrated a response to CPT-11 prior to radiotherapy were allowed to continue the drug after radiation until disease progression or unacceptable toxicity. A 25% to 50% dose reduction was made for grade III-IV toxicity. Responses were assessed after every course by gadolinium-enhanced MRI of the brain and spine. Twenty-two patients received a median of 2 courses of CPT-11 (range, 1-16). Responses were seen in 4 of 9 patients with GBM or anaplastic astrocytoma (44%; 95% confidence interval, 11%-82%) (complete response in 2 patients with recurrent GBM lasting 9 months and 48+ months; partial response in one patient with a newly diagnosed midbrain GBM lasting 18 months prior to radiotherapy; and partial response lasting 11 months in 1 patient with recurrent anaplastic astrocytoma), 1 of 5 patients with recurrent ependymoma (partial response initially followed by stable disease lasting 11 months), and none of 5 patients with recurrent diffuse pontine glioma. Two of 3 patients with medulloblastoma/primitive neuroectodermal tumor had stable disease for 9 and 13 months. Toxicity was mainly myelosuppression, with 12 of 22 patients (50%) suffering grade II-IV neutropenia. Seven patients required dose reduction secondary to neutropenia. CPT-11, given in this schedule, appears to be active in children with malignant glioma, medulloblastoma, and ependymoma with acceptable toxicity. Ongoing studies will demonstrate if activity of CPT-11 can be enhanced when combined with alkylating agents, including carmustine and temozolomide.
References
Benedetti, M.S. (2000) Enzyme induction and inhibition by new antiepileptic drugs: A review of human studies. Fundam. Clin. Pharmacol. 14,301 -319.[ISI][Medline]
Blaney, S., Berg, S.L., Pratt, C., Weitman, S., Sullivan, J.,
Luchtman-Jones, L., and Bernstein, M. (2001) A phase I study of
irinotecan in pediatric patients: A Pediatric Oncology Group study.
Clin. Cancer Res. 7,32
-37.
Chen, Z.S., Furukawa, T., Sumizawa, T., Ono, K., Ueda, K., Seto,
K., and Akiyama, S.I. (1999a) ATP-dependent efflux of CPT-11 and
SN-38 by the multidrug resistance protein (MRP) and its inhibition by
PAK-104P. Mol. Pharmacol.
55,921
-928.
Chen, Z.S., Sumizawa, T., Furukawa, T., Ono, K., Tani, A., Komatsu, M., and Akiyama, S. (1999b) An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells. Cancer Lett. 138,13 -22.[CrossRef][Medline]
Chu, X.Y., Suzuki, H., Ueda, K., Kato, Y., Akiyama, S., and
Sugiyama, Y. (1999) Active efflux of CPT-11 and its metabolites
in human KB-derived cell lines. J. Pharmacol. Exp.
Ther. 288,735
-741.
Coggins, C.A., Elion, G.B., Houghton, P.J., Hare, C.B., Keir, S., Colvin, O.M., Bigner, D.D., and Friedman, H.S. (1998) Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother. Pharmacol. 41,485 -490.[CrossRef][ISI][Medline]
Dunkel, I.J., Boyett, J.M., Yates, A., Rosenblum, M., Garvin, J.H.,
Bostrom, B.C., Goldman, S., Sender, L.S., Gardner, S.L., Li, H., Allen, J.C.,
and Finlay, J.L. (1998) High-dose carboplatin, thiotepa, and
etoposide with autologous stem-cell rescue for patients with recurrent
medulloblastoma. Children's Cancer Group. J. Clin.
Oncol. 16,222
-228.
Feun, L.G., Savaraj, N., and Landy, H.J. (1994) Drug resistance in brain tumors. J. Neurooncol. 20,165 -176.[CrossRef][Medline]
Finlay, J.L. (1999) The role of high-dose chemotherapy and stem cell rescue in the treatment of malignant brain tumors: A reappraisal. Pediatr. Transplant. 3 (Suppl. 1),87 -95.
Finlay, J.L., Goldman, S., Wong, M.C., Cairo, M., Garvin, J., August, C., Cohen, B.H., Stanley, P., Zimmerman, R.A., Bostrom, B., Geyer, J.R., Harris, R.E., Sanders, J., Yates, A.J., Boyett, J.M., and Packer, R.J. (1996) Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. J. Clin. Oncol. 14,2495 -2503.[Abstract]
Friedman, H.S., Petros, W.P., Friedman, A.H., Schaaf, L.J., Kerby,
T., Lawyer, J., Parry, M., Houghton, P.J., Lovell, S., Rasheed, K., Cloughsey,
T., Stewart, E.S., Colvin, O.M., Provenzale, J.M., McLendon, R.E., Bigner,
D.D., Cokgor, I., Haglund, M., Rich, J., Ashley, D., Malczyn, J., Elfring,
G.L., and Miller, L.L. (1999) Irinotecan therapy in adults with
recurrent or progressive malignant glioma. J. Clin.
Oncol. 17,1516
-1525.
Furman, W.L., Stewart, C.F., Poquette, C.A., Pratt, C.B., Santana,
V.M., Zamboni, W.C., Bowman, L.C., Ma, M.K., Hoffer, F.A., Meyer, W.H., Pappo,
A.S., Walter, A.W., and Houghton, P.J. (1999) Direct translation
of a protracted irinotecan schedule from a xenograft model to a phase I trial
in children. J. Clin. Oncol.
17,1815
-1824.
Graham, M.L., Herndon, J.E., II, Casey, J.R., Chaffee, S., Ciocci,
G.H., Krischer, J.P., Kurtzberg, J., Laughlin, M.J., Longee, D.C., Olson,
J.F., Paleologus, N., Pennington, C.N., and Friedman, H.S. (1997)
High-dose chemotherapy with autologous stem-cell rescue in patients with
recurrent and high-risk pediatric brain tumors. J. Clin.
Oncol. 15,1814
-1823.
Hare, C.B., Elion, G.B., Houghton, P.J., Houghton, J.A., Keir, S., Marcelli, S.L., Bigner, D.D., and Friedman, H.S. (1997) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol. 39,187 -191.[CrossRef][ISI][Medline]
Henson, J.W., Cordon-Cardo, C., and Posner, J.B. (1992) P-glycoprotein expression in brain tumors. J. NeuroOncol. 14,37 -43.[Medline]
Houghton, P.J., Stewart, C.F., Thompson, J., Santana, V.M., Furman, W.L., and Friedman, H.S. (1998) Extending principles learned in model systems to clinical trials design. Oncology (Huntingt.) 12,84 -93.
Houghton, P.J., Stewart, C.F., Cheshire, P.J., Richmond, L.B.,
Kirstein, M.N., Poquette, C.A., Tan, M., Friedman, H.S., and Brent, T.P.
(2000) Antitumor activity of temozolomide combined with
irinotecan is partly independent of O6-methylguanine-DNA
methyltransferase and mismatch repair phenotypes in xenograft models.
Clin. Cancer Res. 6,4110
-4118.
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K.
(1991) Intracellular roles of SN-38, a metabolite of the
camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
Cancer Res. 51,4187
-4191.
Kono, A., and Hara, Y. (1991) Conversion of CPT-11 into SN-38 in human tissues [Japanese]. Gan To Kagaku Ryoho 18,2175 -2178.[Medline]
Levy, R.H. (1995) Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 36 (Suppl. 5),S8 -S13.
Patel, V.J., Elion, G.B., Houghton, P.J., Keir, S., Pegg, A.E.,
Johnson, S.P., Dolan, M.E., Bigner, D.D., and Friedman, H.S.
(2000) Schedule-dependent activity of temozolomide plus CPT-11
against a human central nervous system tumor-derived xenograft.
Clin. Cancer Res. 6,4154
-4157.
Phillips, P.C. (1991) Antineoplastic drug resistance in brain tumors. Neurol. Clin. 9, 383-404.[Medline]
Pommier, Y., Tanizawa, A., and Kohn, K.W. (1994) Mechanisms of topoisomerase I inhibition by anticancer drugs. Adv. Pharmacol. 29B,73 -92.
Pourquier, P., Waltman, J.L., Urasaki, Y., Loktionova, N.A., Pegg,
A.E., Nitiss, J.L., and Pommier, Y. (2001) Topoisomerase
I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine:
Trapping of topoisomerase I by the O6-methylguanine.
Cancer Res. 61,53
-58.
Ratain, M.J. (2000) Insights into the pharmacokinetics
and pharmacodynamics of irinotecan. Clin. Cancer Res.
6,3393
-3394.
Rothenberg, M.L., Kuhn, J.G., Schaaf, L.J., Drengler, R.L., Eckhardt, S.G., Villalona-Calero, M.A., Hammond, L., Miller, L.L., Petit, R.G., Rowinsky, E.K., and Von Hoff, D.D. (1998) Alternative dosing schedules for irinotecan. Oncology (Huntingt.) 12 (Suppl. 6),68 -71.
Santos, A., Zanetta, S., Cresteil, T., Deroussent, A., Pein, F., Raymond, E., Vernillet, L., Risse, M.L., Boige, V., Gouyette, A., and Vassal, G. (2000) Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin. Cancer. 6,2012 -2020.
Slichenmyer, W.J., Rowinsky, E.K., Grochow, L.B., Kaufmann, S.H., and Donehower, R.C. (1994) Camptothecin analogues: Studies from the Johns Hopkins Oncology Center. Cancer Chemother. Pharmacol. 34,S53 -S57.
Vassal, G., Boland, I., Santos, A., Bissery, M.C., Terrier-Lacombe, M.J., Morizet, J., Sainte-Rose, C., Lellouch-Tubiana, A., Kalifa, C., and Gouyette, A. (1997) Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastomaxenografts in nude mice. Int. J. Cancer 73,156 -163.[CrossRef][Medline]
Vassal, G., Pondarre, C., Boland, I., Cappelli, C., Santos, A., Thomas, C., Lucchi, E., Imadalou, K., Pein, F., Morizet, J., and Gouyette, A. (1998) Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie 80,271 -280.[Medline]
von Hoff, D. (1996) Future directions for clinical research with CPT-11 (irinotecan). Eur. J. Cancer 32A (Suppl. 3),S9 -S12.
This article has been cited by other articles:
|
|
 |
|
  J. Mora, O. Cruz, S. Gala, and R. Navarro Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin Neuro-oncol, January 1, 2007; 9(1): 39 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Kushner, K. Kramer, S. Modak, and N.-K. V. Cheung Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma J. Clin. Oncol., November 20, 2006; 24(33): 5271 - 5276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Brandes, A. Tosoni, U. Basso, M. Reni, F. Valduga, S. Monfardini, P. Amista, L. Nicolardi, G. Sotti, and M. Ermani Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) J. Clin. Oncol., December 1, 2004; 22(23): 4779 - 4786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. De Cesare, G. Pratesi, S. Veneroni, R. Bergottini, and F. Zunino Efficacy of the Novel Camptothecin Gimatecan against Orthotopic and Metastatic Human Tumor Xenograft Models Clin. Cancer Res., November 1, 2004; 10(21): 7357 - 7364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Wagner, K. R. Crews, L. C. Iacono, P. J. Houghton, C. E. Fuller, M. B. McCarville, R. E. Goldsby, K. Albritton, C. F. Stewart, and V. M. Santana Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors Clin. Cancer Res., February 1, 2004; 10(3): 840 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Grossman, A. O'Neill, M. Grunnet, M. Mehta, J. L. Pearlman, H. Wagner, M. Gilbert, H. B. Newton, and R. Hellman Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394 J. Clin. Oncol., April 15, 2003; 21(8): 1485 - 1491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-K. Souid, R. L. Dubowy, S. M. Blaney, L. Hershon, J. Sullivan, W. D. McLeod, and M. L. Bernstein Phase I Clinical and Pharmacologic Study of Weekly Cisplatin and Irinotecan Combined with Amifostine for Refractory Solid Tumors Clin. Cancer Res., February 1, 2003; 9(2): 703 - 710. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
